PT Prodia Diagnostic Line, the medical-diagnostics manufacturing arm of Indonesia's Prodia healthcare group, is launching a small initial public offering on the Jakarta exchange in July, aiming to raise up to 62.75 billion rupiah, about 3.5 million US dollars, much of which will go toward paying down bank debt.
The company, which will trade under the ticker PRDL, is offering up to 522.9 million new shares, equal to 30 percent of its enlarged capital, at a price range of 100 to 120 rupiah each, according to its preliminary prospectus. Bookbuilding runs from June 18 to 23, with regulatory clearance from the Financial Services Authority (OJK) targeted for June 29 and the public offering set for July 1 to 7. The shares are due to list on the Indonesia Stock Exchange on July 9. Sucor Sekuritas is the underwriter, and the company has set aside up to 36.6 million shares, or 7 percent of the offering, for an employee stock allocation program.
What PRDL does
PRDL makes in-vitro diagnostic (IVD) products, the devices and reagents used in laboratory testing across clinical chemistry, hematology, immunology and molecular biology. The company says its distribution network reaches 370 of Indonesia's districts and cities. It is part of the Prodia Group, which has more than 45 years in clinical chemistry and whose flagship, the listed clinical-laboratory chain Prodia Widyahusada (PRDA), is one of the country's largest diagnostics networks.
Ownership before the listing is split among PT Prodia Utama with 51 percent, Prodia Widyahusada with 39 percent, and Germany's Diasys Diagnostic Systems GmbH with 10 percent, giving the manufacturer a foreign technical partner alongside its domestic parents.
Financially, PRDL is small but growing. Revenue rose about 27 percent in 2025 to 74.3 billion rupiah, around 4 million dollars, while net profit climbed nearly 70 percent to 16.9 billion rupiah. The company reported total assets of 194.4 billion rupiah and equity of 83 billion rupiah.
Where the money goes
Most of the proceeds are earmarked for the balance sheet rather than growth. About 35.67 billion rupiah will repay principal on credit facilities from Bank Central Asia and Bank Pan Indonesia. Roughly 28.92 percent of the net proceeds is allocated to capital spending, including production machinery, calibration equipment, operating vehicles, software, a production-floor revamp and an additional air-handling unit for its biomolecular laboratory. The remaining 8.51 percent is set aside for working capital, covering raw materials, product development and marketing.
PRDL says the listing is intended to strengthen its standing as a domestic manufacturer of diagnostic devices and to expand production capacity to capture rising demand for healthcare services in Indonesia. That positioning aligns with a broader government effort to localize more of the country's medical-device supply chain and reduce reliance on imports.
A modest float in a cold market
By any measure, this is a small offering. At up to 3.5 million dollars, the raise is tiny even by Jakarta standards, and the bulk of it repairs the balance sheet rather than funding expansion. The prospectus flags two main risks for investors: the company's dependence on government spending in the health sector, and the possibility of thin trading in the shares once they are listed.
The timing is also challenging. Indonesia's IPO market has been subdued through 2026 as the benchmark Jakarta Composite Index slid about 29 percent and global investors turned cautious on the country, with some larger issuers looking offshore. Against that backdrop, PRDL is a domestic, modest listing rather than a marquee deal.
For the Prodia group, however, the offering puts a homegrown diagnostics manufacturer on the public market at a moment when Indonesia is keen to build more of its healthcare supply chain at home. Whether investors reward that story, or treat a small-cap medical-device maker with caution, will become clearer when the shares begin trading on July 9.
0 Komentar